The largest database of trusted experimental protocols

12 protocols using biospot software

1

SARS-CoV-2 Antiviral Susceptibility Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antiviral susceptibilities were determined by using a focus reduction assay as previously reported2 (link)–4 (link),36 (link). Briefly, VeroE6-TMPRSS2-T2A-ACE2 cells in 96-well plates were infected with SARS-CoV-2 at 100–400 focus forming unit/well. After a 1-h incubation at 37 °C, the inoculum was replaced with 1% Methyl Cellulose 400 (FUJIFILM Wako Pure Chemical Corporation) in culture medium containing serial dilutions of the antiviral compounds. The cells were incubated for 18 h at 37 °C and then fixed with formalin. The cells were stained with a mouse monoclonal antibody against SARS-CoV-2 nucleoprotein, clone N45 (TAUNS Laboratories, Inc., Japan), followed by a horseradish peroxidase-labeled goat anti-mouse immunoglobulin (Jackson ImmunoResearch Laboratories Inc.). Foci were visualized by using TrueBlue Substrate (SeraCare Life Sciences). The focus numbers were quantified by using an ImmunoSpot S6 Analyzer, ImmunoCapture software, and BioSpot software (Cellular Technology). The 50% inhibitory concentration (IC50) values and 95% confidence intervals were calculated by using GraphPad Prism 9.3.0 (GraphPad Software).
+ Open protocol
+ Expand
2

Quantifying Chikungunya Virus Infectivity

Check if the same lab product or an alternative is used in the 5 most similar protocols
To quantify infectious virus, plaque assays or focus formation assays were performed as previously described.90 (link) Briefly, for plaque assays, BHK-21 cells were seeded in 6-well plates and inoculated with 10-fold serial dilutions of serum or tissue homogenate in in vitro diluent. After 1 h incubation at 37°C, cells were overlayed with 1% immunodiffusion agarose (MP Biomedical) and incubated for another 40–44 h. Afterward, neutral red stain was added to visualize plaques. For focus formation assay, Vero cells were seeded in 96-well plates and inoculated with 10-fold serial dilutions of serum or tissue homogenate for 2 h at 37°C. Cells were overlayed 0.5% methylcellulose in MEM-alpha plus 10% FBS and incubated for 18 h at 37°C. Following fixation with 1% paraformaldehyde (PFA), CHIKV-infected cells were detected using CHK-11 monoclonal antibody88 (link) at 500 ng/mL, and foci were visualized with TrueBlue Peroxidase substrate (SeraCare 5510–0030) and counted using a CTL Biospot analyzer and Biospot software (Cellular Technology).
+ Open protocol
+ Expand
3

Baloxavir Susceptibility Assay in Humanized Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Baloxavir susceptibilities were determined by using a focus reduction assay as previously described [1 (link)] in humanized MDCK cells (i.e., hCK cells), which express high levels of α2,6-sialoglycans and very low levels of α2,3-sialoglycans [15 (link)]. hCK cells were kindly provided by Dr. Yoshihiro Kawaoka (University of Wisconsin–Madison). hCK cells in 96-well plates were infected with 1000 focus-forming units (FFU)/well of viruses. Virus adsorption was carried out for 1 h at 37 °C and then an equal volume of 1.2% Avicel RC-581 (DuPont Nutrition USA, Wilmington, DE, USA) in culture medium containing serial dilutions (0.025–2500 nM) of baloxavir was added to each well in triplicate. The cells were incubated for 24 h at 34 °C and then fixed with formalin. After the formalin was removed, the cells were immunostained with a mouse monoclonal antibody against influenza A virus nucleoprotein (Merck KGaA, Darmstadt, Germany), followed by a horseradish peroxidase-labeled goat anti-mouse immunoglobulin (SeraCare Life Sciences, Milford, MA, USA). The infected cells were stained with TrueBlue Substrate (SeraCare Life Sciences) and then washed with distilled water. After cell drying, the focus numbers were quantified by using an ImmunoSpot S6 Analyzer, ImmunoCapture software, and BioSpot software (Cellular Technology, Cleveland, OH, USA). The results are expressed as IC50 values.
+ Open protocol
+ Expand
4

FRNT Assay for Chikungunya Virus Antibodies

Check if the same lab product or an alternative is used in the 5 most similar protocols
For FRNT assays, Vero cells were seeded in 96-well plates. Serum samples were heat-inactivated and serially diluted in DMEM/F12 medium with 2% FBS in 96-well plates. Approximately 100 focus-forming units (FFU) of virus stock (CHIKV strain SL15649) was added to each well and the serum plus virus mixture was incubated for 1h at 37°C. At the end of 1h, medium was removed from Vero cells and serum sample plus virus mixture was added for 2 h at 37°C. After 2 h, sample was removed and cells were overlaid with 0.5% methylcellulose in MEM/5% FBS and incubated 18h at 37°C. Cells were fixed with 1% PFA and probed with 500 ng/mL of anti-CHIKV CHK-11 mAb (Pal et al., 2013 (link)) diluted in 1X PBS/0.1% saponin/0.1% bovine serum albumin (BSA) for 2h at room temperature. After washing, cells were incubated with HRP-conjugated goat anti-mouse IgG for 1.5-2 h at room temperature. After washing, CHIKV-positive foci were visualized with TrueBlue substrate and counted using a CTL Biospot analyzer and Biospot software (Cellular Technology, Cleveland, OH). Percent infectivity was calculated compared to a virus only (no serum) control. The FRNT50 value was defined as the reciprocal of the last dilution to exhibit 50% infectivity.
+ Open protocol
+ Expand
5

ZIKV Neutralization Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The FRNT50 assay for ZIKV was performed on NHP serum samples. Briefly, fourfold serially diluted serum samples and ZIKV (strain PRVABC59) (≈100 pfu/ml) were incubated for 1 h at 37 °C and added to Vero cells, with overlay medium added after 1 h. After overnight culture, the 96-well plates were stained with an anti-flavivirus monoclonal antibody (MAB10216, Millipore, Burlington, MA USA) and goat anti-mouse IgG (H + L) horseradish peroxidase (HRP)-conjugated secondary antibody (5220–0341, SeraCare Life Sciences, Milford, MA, USA). TrueBlue Peroxidase Substrate (5510–0030, SeraCare Life Sciences, Milford, MA, USA) was added to the plate and spots counted by CTL Biospot Analyzer and Biospot software (Cellular Technology, Ltd, Cleveland, OH, USA). FRNT50 titres were calculated by interpolation between the two points that spanned 50% neutralisation.
+ Open protocol
+ Expand
6

SARS-CoV-2 Neutralization Assay using FRNT

Check if the same lab product or an alternative is used in the 5 most similar protocols
Neutralization activities of SARS-CoV-2 were determined by using an FRNT as previously described15 (link). Serial dilutions of plasma were mixed with 1,000 focus-forming units of virus per well and incubated for 1 h at 37 °C. The antibody-virus mixture was inoculated on VeroE6/TMPRSS2 cells in 96-well plates in duplicate and incubated for 1 h at 37 °C. An equal volume of 1.2% Avicel RC-581 (DuPont Nutrition) in culture medium was added to each well. The cells were incubated for 24 h at 37 °C and then fixed with formalin. After the formalin was removed, the cells were immunostained with a mouse monoclonal antibody against SARS-CoV-1/2 nucleoprotein (clone 1C7C7 (Sigma-Aldrich)) (1:2,000 dilution), followed bya horseradish peroxidase-labelled goat anti-mouse immunoglobulin (SeraCare Life Sciences) (1:2,000 dilution). The infected cells were stained with TrueBlue Substrate (SeraCare Life Sciences) and then washed with distilled water. After cell drying, the focus numbers were quantified by using an ImmunoSpot S6 Analyzer, ImmunoCapture software, and BioSpot software (Cellular Technology). The results are expressed as the 50% focus reduction neutralization titre (FRNT50). The FRNT50 values were calculated by using GraphPad Prism (GraphPad Software).
+ Open protocol
+ Expand
7

Quantifying Chikungunya Virus Infectivity

Check if the same lab product or an alternative is used in the 5 most similar protocols
To quantify infectious virus, plaque assays or focus formation assays were performed as previously described.90 (link) Briefly, for plaque assays, BHK-21 cells were seeded in 6-well plates and inoculated with 10-fold serial dilutions of serum or tissue homogenate in in vitro diluent. After 1 h incubation at 37°C, cells were overlayed with 1% immunodiffusion agarose (MP Biomedical) and incubated for another 40–44 h. Afterward, neutral red stain was added to visualize plaques. For focus formation assay, Vero cells were seeded in 96-well plates and inoculated with 10-fold serial dilutions of serum or tissue homogenate for 2 h at 37°C. Cells were overlayed 0.5% methylcellulose in MEM-alpha plus 10% FBS and incubated for 18 h at 37°C. Following fixation with 1% paraformaldehyde (PFA), CHIKV-infected cells were detected using CHK-11 monoclonal antibody88 (link) at 500 ng/mL, and foci were visualized with TrueBlue Peroxidase substrate (SeraCare 5510–0030) and counted using a CTL Biospot analyzer and Biospot software (Cellular Technology).
+ Open protocol
+ Expand
8

FRNT Assay for SARS-CoV-2 Neutralization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Focus reduction neutralization tests (FRNTs) were used to determine neutralization activities as an additional platform aside from the plaque assay. Serial dilutions of serum starting at a final concentration of 1:20 were mixed with 103 focus-forming units of virus per well and incubated for 1 hour at 37 °C. A pooled prepandemic serum sample served as a control. The antibody-virus mixture was inoculated onto Vero E6/TMPRSS2 cells (JCRB) in 96-well plates and incubated for 1 hour at 37 °C. An equal volume of methylcellulose solution was added to each well. The cells were incubated for 16 hours at 37°C and then fixed with formalin. After the formalin was removed, the cells were immunostained with a mouse mAb against SARS-CoV-1/2 nucleoprotein [clone 1C7C7 (Sigma-Aldrich)], followed by a HRP-labeled goat anti-mouse immunoglobulin (Sigma-Aldrich; A8924). The infected cells were stained with TrueBlue Substrate (SeraCare Life Sciences) and then washed with distilled water. After drying, the focus numbers were quantified by using an ImmunoSpot S6 Analyzer, ImmunoCapture software, and BioSpot software (Cellular Technology). The IC50 was calculated from the interpolated value from the log(inhibitor) versus normalized response, using variable slope (4 parameters) nonlinear regression performed in GraphPad Prism (version 9.0).
+ Open protocol
+ Expand
9

SARS-CoV-2 Antiviral Susceptibility Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antiviral susceptibilities were determined by using a focus reduction assay as previously reported5 (link)–7 (link). Briefly, VeroE6-TMPRSS2-T2A-ACE2 cells in 96-well plates were infected with the indicated virus at 100–400 focus forming unit/well. After incubation at 37 °C for 1 h, the inoculum was replaced with 1% Methyl Cellulose 400 (FUJIFILM Wako Pure Chemical Corporation) in culture medium containing serial dilutions of the antiviral compounds. The cells were incubated for 18 h at 37 °C and then fixed with formalin. The cells were stained with a mouse monoclonal antibody against SARS-CoV-2 nucleoprotein, clone N45 (TAUNS Laboratories, Inc., Japan), followed by a horseradish peroxidase-labeled goat anti-mouse immunoglobulin (Jackson ImmunoResearch Laboratories Inc.). Foci were visualized by using TrueBlue Substrate (SeraCare Life Sciences). The focus numbers were quantified by using an ImmunoSpot S6 Analyzer, ImmunoCapture software, and BioSpot software (Cellular Technology). The 50% inhibitory concentration (IC50) values and 95% confidence intervals were calculated by using GraphPad Prism 9.3.0 (GraphPad Software).
+ Open protocol
+ Expand
10

SARS-CoV-2 Neutralization Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Neutralization activities of SARS-CoV-2 were determined by using an FRNT as previously described14 (link). Serial dilutions of plasma were mixed with 1,000 focus-forming units of virus/well and incubated for 1 h at 37 °C. The antibody-virus mixture was inoculated on VeroE6/TMPRSS2 cells in 96-well plates in duplicate and incubated for 1 h at 37 °C. An equal volume of 1.2% Avicel RC-581 (DuPont Nutrition USA) in culture medium was added to each well. The cells were incubated for 24 h at 37 °C and then fixed with formalin. After the formalin was removed, the cells were immunostained with a mouse monoclonal antibody against SARS-CoV-1/2 nucleoprotein [clone 1C7C7 (Sigma-Aldrich)], followed by a horseradish peroxidase-labeled goat anti-mouse immunoglobulin (SeraCare Life Sciences). The infected cells were stained with TrueBlue Substrate (SeraCare Life Sciences) and then washed with distilled water. After cell drying, the focus numbers were quantified by using an ImmunoSpot S6 Analyzer, ImmunoCapture software, and BioSpot software (Cellular Technology). The results are expressed as the 50% focus reduction neutralization titer (FRNT50). The FRNT50 values were calculated by using GraphPad Prism (GraphPad Software).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!